Mycoplasma pneumoniae is an important cause of human respiratory disease and has been implicated in many acute and chronic airway pathologies including asthma, as well as in a range of extra pulmonary manifestations. The diagnosis of M. pneumoniae has been difficult for many reasons, including their highly fastidious nature. Our discovery of the ADP-ribosylating and vacuolating CARDS TX has enabled us to develop molecular and immunological assays (in collaboration with the diagnostic company Alere) to detect M. pneumoniae based upon the CARDS TX target. We have published these initial assays that continue to evolve in terms of reagent and format optimization. Our long-term objectives of the Diagnostic Core Laboratory will be to provide novel diagnostic assays that are highly sensitive and specific for rapid detection of Mycoplasma pneumoniae, based upon CARDS TX as target. This will allow us to monitor and evaluate the frequency and impact of M. pneumoniae and CARDS TX on asthma-related symptomatology in pediatric and adult patients and pulmonary inflammation, asthma development and pathogenesis in the infected murine model. Our goal is to evaluate specimens such as nasal swabs, throat swabs, sputum and sera from acute and chronic pediatric and adult asthma and control patients to determine the incidence of M. pneumoniae and to correlate the presence of this organism, and CARDS TX-specific antibodies, to pulmonary outcomes using longitudinal assessments. Our hypothesis is that M. pneumoniae through its bona fide virulence determinant, CARDS TX, elicits and exacerbates allergic airway Inflammation in pediatric and adult populations. By accumulating meaningful data from both initial and longitudinal studies of patients and healthy controls, and from experimental data obtained through the murine model of infection and intoxication, we will generate improved diagnostic information which will lead to effective and enhanced treatment modalities.
Our specific aims are as follows: (1) collection and transport of clinical and experimental samples in conjunction with Patient Core and Project 1;(2) process clinical and experimental samples for diagnostic analysis;(3) perform CARDS TX ELISA on all serum samples, both clinical and experimental;(4) evaluate biological samples for levels of CARDS TX protein using a unique antigen capture assay;and (5) perform CARDS TX quantitative real time PCR on samples as described.

Public Health Relevance

Mycoplasma pneumoniae and CARDS toxin induce and exacerbate asthma and allergic airway inflammation in pediatric and adult populations. By accumulating meaningful and improved diagnostic data from both initial and longitudinal studies of patients and healthy controls and from experimental data obtained through the murine model of infection and intoxication, we will generate novel and important diagnostic information which will lead to effective and enhanced treatment modalities.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI070412-08
Application #
8513886
Study Section
Special Emphasis Panel (ZAI1-PA-I)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
8
Fiscal Year
2013
Total Cost
$113,989
Indirect Cost
$28,297
Name
University of Texas Health Science Center San Antonio
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Ji, Hong; Zhang, Xue; Oh, Sunghee et al. (2015) Dynamic transcriptional and epigenomic reprogramming from pediatric nasal epithelial cells to induced pluripotent stem cells. J Allergy Clin Immunol 135:236-44
Medina, Jorge L; Coalson, Jacqueline J; Brooks, Edward G et al. (2014) Mycoplasma pneumoniae CARDS toxin exacerbates ovalbumin-induced asthma-like inflammation in BALB/c mice. PLoS One 9:e102613
Kannan, Thirumalai R; Krishnan, Manickam; Ramasamy, Kumaraguruparan et al. (2014) Functional mapping of community-acquired respiratory distress syndrome (CARDS) toxin of Mycoplasma pneumoniae defines regions with ADP-ribosyltransferase, vacuolating and receptor-binding activities. Mol Microbiol 93:568-81
Somarajan, Sudha R; Al-Asadi, Fadi; Ramasamy, Kumaraguruparan et al. (2014) Annexin A2 mediates Mycoplasma pneumoniae community-acquired respiratory distress syndrome toxin binding to eukaryotic cells. MBio 5:
Burks, Margaret L; Brooks, Edward G; Hill, Vanessa L et al. (2013) Assessing proxy reports: agreement between children with asthma and their caregivers on quality of life. Ann Allergy Asthma Immunol 111:14-9
Krishnan, Manickam; Kannan, T R; Baseman, Joel B (2013) Mycoplasma pneumoniae CARDS toxin is internalized via clathrin-mediated endocytosis. PLoS One 8:e62706
Kannan, T R; Hardy, R D; Coalson, J J et al. (2012) Fatal outcomes in family transmission of Mycoplasma pneumoniae. Clin Infect Dis 54:225-31
Medina, Jorge L; Coalson, Jacqueline J; Brooks, Edward G et al. (2012) Mycoplasma pneumoniae CARDS toxin induces pulmonary eosinophilic and lymphocytic inflammation. Am J Respir Cell Mol Biol 46:815-22
Johnson, Coreen; Kannan, T R; Baseman, Joel B (2011) Cellular vacuoles induced by Mycoplasma pneumoniae CARDS toxin originate from Rab9-associated compartments. PLoS One 6:e22877
Muir, Mark T; Cohn, Stephen M; Louden, Christopher et al. (2011) Novel toxin assays implicate Mycoplasma pneumoniae in prolonged ventilator course and hypoxemia. Chest 139:305-10

Showing the most recent 10 out of 20 publications